Assoc. for Accessible Medicines v. Becerra

CourtDistrict Court, E.D. California
DecidedFebruary 13, 2025
Docket2:20-cv-01708
StatusUnknown

This text of Assoc. for Accessible Medicines v. Becerra (Assoc. for Accessible Medicines v. Becerra) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Assoc. for Accessible Medicines v. Becerra, (E.D. Cal. 2025).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 EASTERN DISTRICT OF CALIFORNIA 10 11 ASSOCIATION FOR ACCESSIBLE No. 2:20-cv-01708-TLN-SCR MEDICINES, 12 Plaintiff, 13 ORDER v. 14 ROB BONTA, in his official capacity as 15 Attorney General of the State of California, 16 Defendant. 17 18 This matter is before the Court pursuant to Defendant Rob Bonta’s, in his official capacity 19 as Attorney General of the State of California (“Defendant” or the “State”), and Plaintiff 20 Association for Accessible Medicines’ (“Plaintiff”) Motions for Summary Judgment. (ECF Nos. 21 68, 70.) Both motions are fully briefed.1 (ECF Nos. 76, 77, 84-2, 85.) For the reasons set forth 22 below, the motions are GRANTED in part and DENIED in part. 23 /// 24 /// 25 /// 26 /// 27 1 Portions of the briefing accompanying this motion have been redacted and instead filed 28 under seal at ECF Nos. 73, 75, 80, and 82. 1 I. FACTUAL AND PROCEDURAL BACKGROUND2 2 On October 7, 2019, California Governor Gavin Newsom signed Assembly Bill 824 (“AB 3 824”) into law. AB 824 creates a presumption that “reverse payment” settlement agreements 4 regarding patent infringement claims between brand-name and generic pharmaceutical companies 5 are anticompetitive and unlawful. 6 Reverse payment settlement agreements arise primarily — if not exclusively — in the 7 context of pharmaceutical drug regulations and suits brought under the statutory provisions of the 8 Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the 9 Hatch-Waxman Act. Under the Hatch-Waxman Act, once a brand-name company has submitted 10 a new prescription drug to the U.S. Food and Drug Administration (“FDA”) and gained approval 11 to market it, a manufacturer of a generic drug with the same active ingredients that is biologically 12 equivalent to the approved brand-name drug can gain approval to market the generic through an 13 abbreviated FDA process. The New Drug Application (“NDA”) process to which new 14 prescription drugs are subject is long, comprehensive, and expensive, whereas the Abbreviated 15 New Drug Application (“ANDA”) process to which generic drugs are subject is substantially less 16 expensive and requires far less testing. 17 In order to gain approval through the FDA, the generic company must file an ANDA. As 18 part of this application, the generic company must assure the FDA that its drug will not infringe 19 on any patents owned by the brand-name company. One way to do so is for the generic company 20 to certify that any listed, relevant patent is invalid or will not be infringed by the manufacture, 21 use, or sale of the generic drug. This is called Paragraph IV certification. Because filing under 22 Paragraph IV indicates there are current patents the generic company asserts are invalid or 23 uninfringed by its product, the Paragraph IV certification is per se a patent infringement and thus 24 the brand-name company can and often does bring suit against the generic drug manufacturer. 25 Settlements of the resulting lawsuits sometimes include reverse payments in which the 26 plaintiff, the brand-name company, pays the defendant, the infringing generic company, a sum of 27 2 The following factual background is taken mostly verbatim from the Court’s December 9, 28 2021, Order granting Plaintiff’s motion for preliminary injunction. (ECF No. 42.) 1 money for the promise that the generic company will keep its drug off the market for an agreed- 2 upon length of time. 3 AB 824 targets these types of settlements. According to the State, AB 824 closes this 4 loophole in the Hatch-Waxman Act and ensures a brand-name company cannot continue to 5 enforce an otherwise weak patent against generic companies through these reverse payment 6 settlement agreements. AB 824 imposes a presumption that a settlement agreement involving a 7 brand-name company compensating the generic company for keeping its drug off the market is 8 anticompetitive under California antitrust law. It also levies a civil penalty against any individual 9 who assists in the violation of the section of three times the value received by the individual due 10 to the violation or $20 million, whichever is greater. 11 Plaintiff is a nonprofit, voluntary association comprised of the leading manufacturers and 12 distributors of generic and biosimilar medicines, manufacturers and distributors of bulk active 13 pharmaceutical ingredients, and suppliers of other goods and services to the generic and 14 biosimilar pharmaceutical industry. Plaintiff previously filed suit in an attempt to invalidate AB 15 824. (ECF No. 1, No. 2:19-cv-02281-TLN-DB.) In the related case, Plaintiff also filed a motion 16 for preliminary injunction (ECF No. 10, No. 2:19-cv-02281-TLN-DB), which the Court denied 17 (ECF No. 29, No. 2:19-cv-02281-TLN-DB). The Court found, primarily due to the nature of 18 Plaintiff’s pre-enforcement attack on AB 824, Plaintiff failed to establish a likelihood of success 19 on the merits or raise serious questions going to the merits. (Id.) The Court concluded that 20 absent a constitutional violation, Plaintiff failed to establish an irreparable harm that was both 21 likely and imminent. (Id.) Plaintiff subsequently filed an interlocutory appeal of the Court’s 22 decision to the Ninth Circuit. (ECF No. 31, No. 2:19-cv-02281-TLN-DB.) The Ninth Circuit 23 heard oral arguments on the matter and ultimately vacated this Court’s order and remanded with 24 instructions to dismiss without prejudice, finding Plaintiff failed to demonstrate its members had 25 an Article III injury in fact and concluding Plaintiff lacked associational standing to bring claims 26 on its members’ behalf. (See ECF Nos. 46–47, No. 2:19-cv-02281-TLN-DB.) The Court 27 subsequently dismissed the suit without prejudice pursuant to the Ninth Circuit’s memorandum 28 and mandate. (ECF Nos. 48–49, No. 2:19-cv-02281-TLN-DB.) 1 On August 25, 2020, Plaintiff filed the instant Complaint alleging near-identical causes of 2 action to its prior suit, once again in an attempt to invalidate AB 824: (1) Declaratory/Injunctive 3 Relief — Commerce Clause — Extraterritoriality; (2) Declaratory/Injunctive Relief — 4 Preemption; (3) Declaratory/Injunctive Relief — Excessive Fines Clause; and (4) 5 Declaratory/Injunctive Relief — Due Process — Burden-Shifting. (ECF No. 1 at 21–33.) On 6 December 9, 2021, the Court granted Plaintiff’s motion for a preliminary injunction, finding 7 Plaintiff sufficiently alleged Article III standing and Plaintiff was likely to succeed on the merits 8 of its dormant Commerce Clause claim. (ECF No. 42.) 9 On February 15, 2022, the Court granted the State’s motion in part to modify the 10 preliminary injunction, allowing the State to enforce the provisions of AB 824 with respect to 11 settlement agreements negotiated, completed, or entered into within California’s borders. (ECF 12 No. 47.) The injunction bars the Attorney General of the State of California, as well as the 13 Attorney General’s officers, agents, employees, attorneys, and all persons in active concert or 14 participation with them from implementing or enforcing AB 824 against Plaintiff, its member 15 entities, or their agents and licensees, with the exception of settlement agreements negotiated, 16 completed, or entered into within California’s borders. (Id.) 17 On September 15, 2023, the State and Plaintiff filed the instant motions for summary 18 judgment. (ECF Nos. 68, 70.) 19 II. STANDARD OF LAW 20 Summary judgment is appropriate when the moving party demonstrates no genuine issue 21 of any material fact exists and the moving party is entitled to judgment as a matter of law. Fed. 22 R. Civ. P. 56(a); Adickes v. S.H. Kress & Co., 398 U.S. 144, 157 (1970).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Baldwin v. G. A. F. Seelig, Inc.
294 U.S. 511 (Supreme Court, 1935)
First Nat. Bank of Ariz. v. Cities Service Co.
391 U.S. 253 (Supreme Court, 1968)
Adickes v. S. H. Kress & Co.
398 U.S. 144 (Supreme Court, 1970)
Edgar v. Mite Corp.
457 U.S. 624 (Supreme Court, 1982)
Phillips Petroleum Co. v. Shutts
472 U.S. 797 (Supreme Court, 1985)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Healy v. Beer Institute
491 U.S. 324 (Supreme Court, 1989)
Wyoming v. Oklahoma
502 U.S. 437 (Supreme Court, 1992)
Smallwood v. Allied Van Lines, Inc.
660 F.3d 1115 (Ninth Circuit, 2011)
United States v. Zackery Lucius Sharp
12 F.3d 605 (Sixth Circuit, 1993)
Carson Harbor Village, Ltd. v. Unocal Corporation
270 F.3d 863 (Ninth Circuit, 2001)
F.T.C. v. Actavis, Inc.
133 S. Ct. 2223 (Supreme Court, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Assoc. for Accessible Medicines v. Becerra, Counsel Stack Legal Research, https://law.counselstack.com/opinion/assoc-for-accessible-medicines-v-becerra-caed-2025.